Autoimmune Hepatitis Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Autoimmune Hepatitis Marketed and Pipeline Drugs Report Overview
Autoimmune Hepatitis (AIH) is four times more common in females than in males and is commonly associated with other autoimmune conditions, including type one diabetes, Hashimoto’s thyroiditis, and celiac disease. The persistent inflammation within the liver observed in AIH can result in scarring, ultimately leading to cirrhosis, liver failure (requiring a liver transplant), and even death.
The Autoimmune Hepatitis marketed, and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing, and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for autoimmune hepatitis (AIH).
Top Sponsors in the AIH Marketed and Pipeline Drugs Market
A few of the top sponsors in the AIH marketed and pipeline drugs market are West China Hospital, West China Hospital of Sichuan University, TaiwanJ Pharmaceuticals Co Ltd, University of Birmingham, Leiden University Medical Center, University Medical Center Utrecht, Tel Aviv Sourasky Medical Center, Catholic University of Louvain, Novartis AG, and Nova Laboratories Ltd. Among the commercial sponsors, TaiwanJ Pharma has sponsored the highest number of clinical trials in AIH over the past 10 years.
AIH Marketed and Pipeline Drugs Market
Buy the full Report for More Sponsors’ Insights into the Autoimmune Hepatitis Marketed and Pipeline Drugs Market, Download a Free Report Sample
Leading Marketed Drugs for Autoimmune Hepatitis
The leading marketed drugs for autoimmune hepatitis are Azathioprine and Budesonide DR. Corticosteroids, such as prednisone/prednisolone (first-line therapy) or budesonide, are the most used treatment options to suppress the immune system.
Autoimmune Hepatitis Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for autoimmune hepatitis pipeline drugs are receptor antagonist, receptor agonist, protein & peptide activator, and ion channel inhibitor. Most pipeline drugs for AIH are receptor antagonists.
Autoimmune Hepatitis Pipeline Drugs Analysis, by Mechanisms of Action
Buy the full Report for More MoA Insights into the Autoimmune Hepatitis Pipeline Drugs Market, Download a Free Report Sample
Autoimmune Hepatitis Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for autoimmune hepatitis pipeline drugs are injection and oral. Injectable therapies make up most of the AIH pipeline.
Autoimmune Hepatitis Pipeline Drugs Analysis, by Routes of Administration
Buy the full Report for More RoA Insights into the Autoimmune Hepatitis Pipeline Drugs Market, Download a Free Report Sample
Autoimmune Hepatitis Pipeline Drugs Segmentation by Molecule Type
Most of the pipeline drugs for AIH are small molecules. Biologics and oligonucleotides are the other significant molecule types in the pipeline of drugs for AIH.
Autoimmune Hepatitis Pipeline Drugs Analysis, by Molecule Types
Buy the full Report for More Molecule Insights into the Autoimmune Hepatitis Pipeline Drugs Market, Download a Free Report Sample
Key Mechanisms of Action | · Receptor Antagonist
· Receptor Agonist · Protein & Peptide Activator · Ion Channel Inhibitor |
Key Routes of Administration | · Injection
· Oral |
Key Molecule Types | · Small Molecule
· Biologic · Oligonucleotide |
Top Sponsors (Marketed and Pipeline Drugs) | · West China Hospital
· West China Hospital of Sichuan University · TaiwanJ Pharmaceuticals Co Ltd · University of Birmingham · Leiden University Medical Center |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Segments Covered in the Report
Autoimmune Hepatitis Pipeline Drugs MoA Outlook
- Receptor Antagonist
- Receptor Agonist
- Protein & Peptide Activator
- Ion Channel Inhibitor
Autoimmune Hepatitis Pipeline Drugs RoA Outlook
- Injection
- Oral
Autoimmune Hepatitis Pipeline Drugs Molecule Type Outlook
- Small Molecule
- Biologic
- Oligonucleotide
Scope
GlobalData’s Autoimmune Hepatitis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the autoimmune hepatitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global autoimmune hepatitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for autoimmune hepatitis pipeline drugs?
The key mechanisms of action in the autoimmune hepatitis pipeline drugs market are receptor antagonist, receptor agonist, protein & peptide activator, and ion channel inhibitor.
-
What are the key routes of administration for autoimmune hepatitis pipeline drugs?
The key routes of administration in the autoimmune hepatitis pipeline drugs market are injection and oral.
-
What are the key molecule types for autoimmune hepatitis pipeline drugs?
The key molecule types in the autoimmune hepatitis pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the top sponsors for the AIH marketed and pipeline drugs market?
A few of the top sponsors for the AIH marketed and pipeline drugs market are West China Hospital, West China Hospital of Sichuan University, TaiwanJ Pharmaceuticals Co Ltd, University of Birmingham, Leiden University Medical Center, University Medical Center Utrecht, Tel Aviv Sourasky Medical Center, Catholic University of Louvain, Novartis AG, and Nova Laboratories Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.